Cargando…

COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?

Detalles Bibliográficos
Autor principal:	Brownlee, Wallace J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Case Report and Clinical Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720354/ https://www.ncbi.nlm.nih.gov/pubmed/32762499 http://dx.doi.org/10.1177/1352458520948211

Ejemplares similares

Business Not As Usual: Implementation Strategies That Support Learning During the COVID-19 Pandemic
por: Cross, Dori A., et al.
Publicado: (2021)

Commentary: Business as usual: A thing of the past
por: Karas, Tomer Z., et al.
Publicado: (2020)

No time for business as usual: can systems thinking help us to accelerate recovery for early child development?
por: Milner, Kate M, et al.
Publicado: (2023)

Physiotherapists during COVID-19: usual business, in unusual times
por: Haines, Kimberley J, et al.
Publicado: (2020)

Tracheostomy for COVID-19: business as usual?
por: McGrath, Brendan A., et al.
Publicado: (2020)

Acute coronary syndrome in COVID-19 times: could it be business as usual?
por: Ferreira, J, et al.
Publicado: (2021)

An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion
por: Alroughani, Raed, et al.
Publicado: (2019)

Business-as-Usual will not Deliver the COVID-19 Vaccines We Need
por: Torreele, Els
Publicado: (2020)

Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19
por: Shin, Robert K., et al.
Publicado: (2022)

Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient
por: Wurm, Hannah, et al.
Publicado: (2020)

Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study
por: Williams, Thomas, et al.
Publicado: (2022)

During the holidays, it was business as usual.
Publicado: (2006)

No more business as usual in China
por: The Lancet Infectious Dieases
Publicado: (2003)

Business as Usual: A Lack of Institutional Innovation in Global Health Governance: Comment on "Global Health Governance Challenges 2016 – Are We Ready?"
por: Lee, Kelley
Publicado: (2016)

The COVID-19 lessons learned for business and governance
por: Eklund, Mehtap A.
Publicado: (2021)

No longer business as usual : fighting bribery and corruption.
Publicado: (2000)

Returning to orthopaedic business as usual after COVID-19: strategies and options
por: de Caro, Francesca, et al.
Publicado: (2020)

Breastfeeding and treatment of multiple sclerosis
por: Celius, Elisabeth G
Publicado: (2020)

COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile
por: Ciampi, Ethel, et al.
Publicado: (2020)

Expert Perspectives on COVID-19 Vaccination for People Living with Multiple Sclerosis
por: Shin, Robert K., et al.
Publicado: (2021)

Paradigms in multiple sclerosis: time for a change, time for a unifying concept
por: Krone, Bernd, et al.
Publicado: (2011)

Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk
por: Hartung, Hans-Peter, et al.
Publicado: (2021)

The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients
por: Kloc, Malgorzata, et al.
Publicado: (2020)

Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis
por: Filippi, Massimo, et al.
Publicado: (2021)

Business as usual? Psychological support at a distance
por: Payne, Lara, et al.
Publicado: (2020)

Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy
por: Heming, Michael, et al.
Publicado: (2023)

The business of medicine and surgery with medical aid: Time for regulation and legislation?
por: Noorbhai, Habib, et al.
Publicado: (2018)

Memory and Consciousness—Usually in Tandem but Sometimes Apart
por: Madan, Christopher R.
Publicado: (2023)

Pathway choice and post-Covid tourism: Inclusive growth or business as usual?
por: Jeyacheya, Julia, et al.
Publicado: (2022)

SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy
por: Schulte, Eva C., et al.
Publicado: (2021)

Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): A report from Iran
por: Sahraian, Mohammad Ali, et al.
Publicado: (2020)

Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study
por: Barzegar, Mahdi, et al.
Publicado: (2021)

Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study
por: Sedaghat, Nahad
Publicado: (2021)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

Multiple Sclerosis in Pregnancy: A Commentary on Disease Modification and Symptomatic Drug Therapies
por: Iyer, Priyanka, et al.
Publicado: (2022)

Tolerogenic vaccines for Multiple Sclerosis
por: Mannie, Mark D., et al.
Publicado: (2013)

Remote delivery of CBT training, clinical supervision and services: in times of crisis or business as usual
por: Cromarty, Paul, et al.
Publicado: (2020)

Business of medicine
por: Abdullah, BJJ
Publicado: (2010)

Critical care rehabilitation trials: the importance of ‘usual care’
por: Parker, Ann, et al.
Publicado: (2013)

Hypotension and hypovolemia during hemodialysis: is the usual suspect innocent?
por: Berger, David, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kkcqp7bd8k67esecdk5n9s1ps4